Alumis Inc. (ALMS)
NASDAQ
Closed
Sep 22, 2026
Day's Range
7.7052 wk Range
3.76Overview - ALMS - Alumis Inc.
Key Statistics
Valuation
Enterprise Value
815.54M
P/E (Trailing)
‪0.16‬
P/E (Forward)
‪-3.19‬
PEG Ratio
‪-0.00056‬
Price / Sales (TTM)
‪160.61‬
Price / Book
‪2.60‬
EV / EBITDA
‪-1.93‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-6,439.89%‬
Return on Assets
‪-45.34%‬
Return on Equity
‪-93.64%‬
Ownership
Shares Outstanding
128.50M
Float
104.39M
Short % of Shares Outstanding
‪7.27%‬
Held by Insiders
‪0.52%‬
Held by Institutions
‪93.39%‬
Price stats
Beta
‪-0.79‬
50-Day Avg
‪24.30‬
200-Day Avg
‪22.25‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
10 analysts
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ALMS - Alumis Inc.
Peers - ALMS - Alumis Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ALMSNASDAQAlumis Inc.1.18BMarket Cap+52.29%52-week change0.17P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ALMS - Alumis Inc.
About
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company’s current pipeline centers on oral TYK2 inhibitors designed to address conditions such as plaque psoriasis and systemic lupus erythematosus, alongside a CNS-penetrant TYK2…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
